NASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Price, News & Analysis $3.20 +0.02 (+0.63%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$3.19 -0.01 (-0.19%) As of 07:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bicycle Therapeutics Stock (NASDAQ:BCYC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bicycle Therapeutics alerts:Sign Up Key Stats Today's Range$3.12▼$3.2250-Day Range$3.18▼$4.0152-Week Range$3.07▼$7.83Volume445,392 shsAverage Volume410,026 shsMarket Capitalization$224.29 millionP/E RatioN/ADividend YieldN/APrice Target$13.57Consensus RatingHold Company Overview Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access. Its research includes Bicycle toxin conjugates, which pair target-binding peptides with therapeutic payloads, as well as radiopharmaceutical and immune-modulating approaches. The company’s products are investigational and are being developed through clinical and preclinical research.AI Generated. May Contain Errors. Read More Bicycle Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreBCYC MarketRank™: 2.739095638255 of 5 starsBicycle Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 432nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingBicycle Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 5 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialBicycle Therapeutics has a consensus price target of $13.57, representing about 324.1% upside from its current price of $3.20.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Bicycle Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($2.30) to ($2.35) per share.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.07% of the float of Bicycle Therapeutics has been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 8.38.Change versus previous monthShort interest in Bicycle Therapeutics has recently increased by 11.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.95 News SentimentBicycle Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Bicycle Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,848.00 in company stock.Percentage Held by Insiders22.00% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bicycle Therapeutics' insider trading history. Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCYC Stock News HeadlinesBicycle Therapeutics (NASDAQ:BCYC) Cut to Sell at Wall Street ZenNovember 17 at 1:34 AM | americanbankingnews.comBicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock Has Average Price Target of $13.57 According to BrokeragesNovember 16 at 3:01 AM | americanbankingnews.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 18 at 1:00 AM | American Alternative (Ad)Bicycle Therapeutics Advances Cancer Programs While Keeping Details Close, Oppenheimer SaysOctober 31, 2026 | finance.yahoo.comBicycle Therapeutics Reports Q3 Results; Nuzefatide Updates Expected In 2027October 29, 2026 | rttnews.comBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial ResultsOctober 29, 2026 | finance.yahoo.comBicycle Therapeutics Ltd. ADRSeptember 24, 2026 | barrons.comRBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)August 5, 2026 | theglobeandmail.comSee More Headlines BCYC Stock Analysis - Frequently Asked Questions How have BCYC shares performed this year? Bicycle Therapeutics' stock was trading at $7.08 on January 1st, 2026. Since then, BCYC shares have decreased by 54.8% and is now trading at $3.20. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) posted its earnings results on Thursday, October, 29th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.25. The business had revenue of $34.06 million for the quarter, compared to analyst estimates of $12.22 million. Bicycle Therapeutics had a negative net margin of 169.75% and a negative trailing twelve-month return on equity of 26.02%. When did Bicycle Therapeutics IPO? Bicycle Therapeutics (BCYC) raised $65 million in an IPO on Thursday, May 23rd 2019. The company issued 4,333,333 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Bicycle Therapeutics' major shareholders? Bicycle Therapeutics' top institutional shareholders include Marshall Wace LLP (1.19%), Pinnacle Associates Ltd. (0.23%), Goldman Sachs Group Inc. (0.14%) and Jump Financial LLC (0.12%). Insiders that own company stock include Bros Advisors Lp Baker, Kevin Lee, Alistair Milnes, Michael Skynner, Jennifer Scott Perry, Alethia Young, Santiago Arroyo, Travis Alvin Thompson, Nicholas Keen, Michael Charles Ferguso Hannay, Nigel Crockett and Robert Charles Swanton. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Rocket Pharmaceuticals (RCKT), Allogene Therapeutics (ALLO), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), Palantir Technologies (PLTR) and PayPal (PYPL). Company Calendar Last Earnings10/29/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (56m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BCYC's financial health is in the Red zone, according to TradeSmith. BCYC has been in this zone for over 56 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCYC CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees288Year Founded2009Price Target and Rating Average Price Target for Bicycle Therapeutics$13.57 High Price Target$36.00 Low Price Target$7.00 Potential Upside/Downside+324.1%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$218.96 million Net Margins-169.75% Pretax Margin-166.52% Return on Equity-26.02% Return on Assets-22.30% Debt Debt-to-Equity RatioN/A Current Ratio12.09 Quick Ratio12.09 Sales & Book Value Annual Sales$72.86 million Price / Sales3.08 Cash FlowN/A Price / Cash FlowN/A Book Value$7.21 per share Price / Book0.44Miscellaneous Outstanding Shares70,090,000Free Float54,673,000Market Cap$224.29 million OptionableOptionable Beta1.59 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:BCYC) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.